Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutation - Concepedia

Concepedia

Publication | Open Access

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutation

DOI Full Paper Access

493

Citations

25

References

2011

Year

John P. Clancy, Steven M. Rowe, Frank J. Accurso, Moira L. Aitken, Raouf Amin, Melissa A. Ashlock, Manfred Ballmann, Michael Boyle, Inez Bronsveld, Preston W. Campbell,

Abstract

NCT00865904.

References

	Year	Citations

Page 1